Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

46Background: Androgen deprivation therapy (ADT) is the cornerstone of treatment for mCSPC patients. Clinical trials have recently shown that adding docetaxel (DOC) or novel hormonal therapies (NHT...